A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 3, 2003, Pages 473-476

  Gosling, Roly D ^a   Heifets, Leonid ^b   Gillespie, Stephen H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Clinical trials; Mathematical models; Phase II; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANALYSIS OF VARIANCE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; INTERMETHOD COMPARISON; KENYA; KRUSKAL WALLIS TEST; MATHEMATICAL MODEL; MONOTHERAPY; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; NONPARAMETRIC TEST; SPUTUM ANALYSIS; STATISTICAL SIGNIFICANCE; TANZANIA; TUBERCULOSIS; UNITED STATES; VALIDATION PROCESS;

ALGORITHMS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; COLONY COUNT, MICROBIAL; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 0141852793     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg345     Document Type: Article

References (19)

1. Dye, C., Fengzeng, Z., Scheele, S. et al. (2000). Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. International Journal of Epidemiology 29, 558-64.
2. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. (1997). Anti-Tuberculosis Drug Resistance in the World. WHO, Geneva.
3. Walley, J. D., Khan, M. A., Newell, J. N. et al. (2001). Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 357, 664-9.
4. Pablos-Mendez, A. (2000). Working alliance for TB drug development, Cape Town, South Africa, February 8th, 2000. International Journal of Tuberculosis and Lung Disease 4, 489-90.
5. Jindani, A., Aber, V. R., Edwards, E. A. et al. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. American Review of Respiratory Diseases 121, 939-49.
6. Botha, F. J., Sirgel, F. A., Parkin, D. P. et al. (1996). Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. South African Medical Journal 86, 155-8.
7. Donald, P. R., Sirgel, F. A., Botha, F. J. et al. (1997). The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 156, 895-900.
8. Donald, P. R., Sirgel, F. A., Kanyok, T. P. et al. (2000). Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 44, 3285-7.
9. Sirgel, F. A., Botha, F. J., Parkin, D. P. et al. (1993). The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. Journal of Antimicrobial Chemotherapy 32, 867-75.
10. Sirgel, F. A., Botha, F. J., Parkin, D. P. et al. (1997). The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 156, 901-5.
11. Sirgel, F. A., Donald, P. R., Odhiambo, J. et al. (2000). A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 45, 859-70.
12. Kennedy, N., Fox, R., Kisyombe, G. M. et al. (1993). Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. American Review of Respiratory Diseases 148, 1547-51.
13. Hafner, R., Cohn, J. A., Wright, D. J. et al. (1997). Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. American Journal of Respiratory and Critical Care Medicine 156, 918-23.
14. Sirgel, F., Venter, A. & Mitchison, D. (2001). Sources of variation in studies of the early bactericidal activity of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 47, 177-82.
15. Gillespie, S. H., Gosling, R. D. & Charalambous, B. M. (2002). A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. American Journal of Respiratory and Critical Care Medicine 166, 31-5.
16. O'Brien, R. J. (2001). Scientific blueprint for tuberculosis drug development. Tuberculosis 81, 19-45.
17. O'Brien, R. J. (2002). Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to anti-tuberculosis drug development? American Journal of Respiratory and Critical Care Medicine 166, 3-4.
18. Mitchison, D. A. (1985). The action of anti-tuberculosis drugs in short-course chemotherapy. Tubercle 66, 219-25.
19. 1 slopes. In The Treatment of Chronic Bronchitis and Emphysema, pp. 170-4. Oxford University Press, Oxford, UK.